GU Cancers
US Focus Meeting 2026
📍 Hyatt Regency Boston Harbor, 101 Harborside Dr, Boston, MA 02128
🗓️ August 14 - 15, 2026
Dear Colleagues and Friends,
We are delighted to extend our warmest invitation to the GU Cancers Focus Meeting 2026, to be held on August 14 - 15, 2026.
Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing GU Cancers research and patient treatment.
This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.
Chairs of GU Cancers US Focus Meeting 2026:
Toni K. Choueiri, MD
Dana-Farber Cancer Institute, Boston, MA
Rana R. McKay, MD
UC San Diego, CA
Supporters to be announced...
Interested in supporting this meeting? Get in contact:
aimee.williams@md-education.com
Agenda & Faculty
August 14, 2026 | Day 1
Session I: Initial Systemic Treatment in RCC
Moderated by:
Michael Serzan, MD
Dana-Farber Cancer Institute, Boston, MA
09:05 AM
Adjuvant Immunotherapy: Patient Selection and Implementation
Bradley A. McGregor, MD
Dana-Farber Cancer Institute, Boston, MA
09:20 AM
IO Combination Strategies in Clear Cell RCC
Wenxin "Vincent" Xu, MD
Dana-Farber Cancer Institute, Boston, MA
09:35 AM
Systemic Treatment Approaches for Variant Histologies
Sumanta K. Pal, MD
City of Hope, Duarte, CA
09:50 AM
Case Discussion: Adjuvant IO Failure and Progression
Michael Serzan, MD
Dana-Farber Cancer Institute, Boston, MA
Session II: Post-Progression Treatment of Advanced RCC
Moderated by:
Xin Gao, MD
Massachusetts General Hospital, Boston, MA
10:40 AM
HIF2α Inhibition in RCC
Yu-Wei Chen, MD, MS
UC San Diego Health, CA
10:55 AM
VEGF TKI Selection and Sequencing
Thai Huu Ho, MD, PhD
MUSC Health, Charleston, SC
11:10 AM
Toxicity Management: IO, VEGF, and HIF Inhibitors
Stephanie A. Berg, DO
Dana-Farber Cancer Institute, Boston, MA
11:25 AM
Case Discussion: Treatment Options After IO and VEGF Failure
Xin Gao, MD
Massachusetts General Hospital, Boston, MA
Session III: Perioperative Management of Muscle-Invasive Bladder Cancer
Moderated by:
Alexandra Drakaki, MD, PhD
UCLA Health, Los Angeles, CA
01:40 PM
Bladder-Sparing Treatment Approaches
Kent W. Mouw, MD, PhD
Dana-Farber Cancer Institute, Boston, MA
01:55 PM
Perioperative Immunotherapy Integration
Joaquim Bellmunt, MD, PhD
Dana-Farber Cancer Institute, Boston, MA
02:10 PM
ctDNA in Perioperative Bladder Cancer
Matthew D. Galsky, MD
Icahn School of Medicine at Mount Sinai, New York, NY
02:25 PM
Case Discussion: T3 MIBC with Positive ctDNA After Treatment
Alexandra Drakaki, MD, PhD
UCLA Health, Los Angeles, CA
Session IV: Treatment Strategies of Metastatic Urothelial Cancer Treatment
Moderated by:
Mark N. Stein, MD
Columbia University Irving Medical Center, New York, NY
04:00 PM
First-Line Treatment Selection: Chemo vs IO vs Maintenance
Jonathan E. Rosenberg, MD
Memorial Sloan Kettering Cancer Center, New York, NY
04:15 PM
Molecular Testing and Targeted Therapy Implementation
Abhishek Tripathi, MD
City of Hope, Duarte, CA
04:30 PM
ADC and Targeted Therapy Toxicity Management
Charlene Mantia, MD
Dana-Farber Cancer Institute, Boston, MA
04:45 PM
Case Discussion: HER2+ Metastatic Disease Treatment Decisions
Mark N. Stein, MD
Columbia University Irving Medical Center, New York, NY
August 15, 2026 | Day 2
Session V: Approach to Biochemical Recurrent Prostate Cancer
Moderated by:
David J. Einstein, MD
Beth Israel Deaconess Medical Center, Boston, MA
09:05 AM
PSMA PET Imaging and Oligometastatic Treatment
Tyler Seibert, MD, PhD
UC San Diego Health, CA
09:20 AM
High-Risk BCR: Definition and Treatment Approaches
Michael Hurwitz, MD, PhD
Yale School of Medicine, New Haven, CT
09:35 AM
Systematic treatment approaches for BCR
EA
Emmanuel S. Antonarakis, MD
University of Minnesota, Masonic Cancer Center
09:50 AM
Case Discussion: Oligometastatic BCR Treatment Selection
David J. Einstein, MD
Beth Israel Deaconess Medical Center, Boston, MA
Session VI: Management of Metastatic Hormone-Sensitive Prostate Cancer
Moderated by:
Philip J. Saylor, MD
Massachusetts General Hospital, Boston, MA
10:40 AM
Triple Therapy: Evidence and Implementation
David R. Wise, MD, PhD
NYU Langone Medical Center, New York, NY
10:55 AM
Novel Triple Combinations: PARP, PSMA, and AKT Inhibitors
PR
Praful Ravi, MB, BChir, MRCP
Dana-Farber Cancer Institute, Boston, MA
11:10 AM
ARSI Selection: Factors for Agent Choice
DP
Daniel P. Petrylak, MD
Yale School of Medicine, New Haven, CT
11:25 AM
Case Discussion: De Novo High Volume mHSPC with Adverse Genetics
Philip J. Saylor, MD
Massachusetts General Hospital, Boston, MA
Session VII: Treatment Strategies for Metastatic Castration-Resistant Prostate Cancer
Moderated by:
Guru P. Sonpavde, MD
Advent Health Cancer Institute, Orlando, FL
01:40 PM
Radiopharmaceutical Integration
Atish D. Choudhury, MD, PhD
Dana-Farber Cancer Institute, Boston, MA
01:55 PM
Genetic Testing and PARP Inhibitor Treatment
Alok K. Tewari, MD, PhD
Dana-Farber Cancer Institute, Boston, MA
2:10 PM
Neuroendocrine Prostate Cancer: Recognition and Treatment
Himisha Beltran, MD
Dana-Farber Cancer Institute, Boston, MA
2:25 PM
Case Discussion: mCRPC Treatment Sequencing Decisions
Guru P. Sonpavde, MD
Advent Health Cancer Institute, Orlando, FL
Session VIII: Novel Therapeutics in Genitourinary Cancers
Moderated by:
Daniel J. George, MD
Duke Health, Durham, NC
04:00 PM
Novel Agents in RCC
David A. Braun, MD, PhD
Yale School of Medicine, New Haven, CT
04:15 PM
Emerging Targeting in Urothelial Carcinoma
Vadim S. Koshkin, MD
UCSF Health, San Francisco, CA
04:30 PM
Next Generation Treatments in Prostate Cancer
Atish D. Choudhury, MD, PhD
Dana-Farber Cancer Institute, Boston, MA
04:45 PM
Case Discussion: Clinical Trial Enrollment and Patient Experience
Daniel J. George, MD
Duke Health, Durham, NC
Aimee Williams
Project Manager
How long has Aimee Williams been in the business?
Aimee Williams has been with MD Education since 2022
About Aimee Williams
I joined MD Education in 2022 as a Project Manager, leveraging my background in events management and passion for high-quality results. After earning a degree in Events Management, I gained hands-on experience managing projects while living in Nashville, TN. Driven and detail-oriented, I thrive in fast-paced environments, ensuring projects meet the highest standards. An avid traveler, I bring creativity and open-mindedness to problem-solving and client relationships.
